Inhibrx, Inc. announced the appointment of David Matly, M.B.A., as Chief Commercial Officer and appointed Kristiina Vuori, M.D., Ph.D. to its Board of Directors, effective October 28, 2021. Dr. Vuori will serve as a member of the Audit Committee and Nominating and Governance Committee of the Board. In connection with this appointment, Inhibrx Chief Scientific Officer and Co-founder, Brendan Eckelman, Ph.D., stepped down from the Board. Mr. Matly brings extensive commercial launch and leadership experience across both orphan diseases and oncology. Mr. Matly joins from Novartis where he served as the global Vice President of the MDS/AML franchise. Since January 2010, Dr. Vuori has served as President of, and has held the Pauline and Stanley Foster Presidential Chair at, Sanford Burnham Prebys Medical Discovery Institute. Dr. Vuori has previously served or is currently serving on the Board of Directors of Bionano Genomics, Inc., Sio Gene Therapies, Forian, Inc., the American Association for Cancer Research, the California Institute for Regenerative Medicine, the California Breast Cancer Research Council and WebMD.